Recent Advances in Multiple Myeloma: Insights from Experts at University of Pennsylvania : Episode 5
Patient Case 2: High-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma
Centering discussion on a patient case of transplant-eligible newly diagnosed multiple myeloma, expert panelists define high-risk disease and how it impacts treatment.
EP: 1.Patient Case 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma
EP: 2.Recent Updates on Treatment Options for Patients With Transplant-Eligible NDMM
EP: 3.Selecting the Optimal Induction Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma
EP: 4.Consolidation and Maintenance Therapy in Transplant-Eligible NDMM
Now Viewing
EP: 5.Patient Case 2: High-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma
EP: 6.Selecting Induction Therapy for Patients With High-Risk Transplant-Eligible NDMM
EP: 7.Transplant-Eligible NDMM: Optimizing Therapy for Efficacy and Tolerability
EP: 8.Patient Case 3: Transplant-Ineligible Newly Diagnosed Multiple Myeloma
EP: 9.Selecting the Optimal Therapy for Patients With Transplant-Ineligible NDMM
EP: 10.Treatment Response and Duration of Therapy in Transplant-Ineligible NDMM
EP: 11.University of Pennsylvania Experts Discuss Treatment Options in Transplant-Eligible and -Ineligible Newly Diagnosed Multiple Myeloma
Recent Videos
Related Content
!["[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fb319d51b3dcc8ae143eae44a72a0aff757b330db-800x533.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation,\" according to the study authors.")
![“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F4de1e119837b011168a7884a19a600b14bb6a258-3600x2400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.")
